Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 9, 2013 - Issue 6
Submit an article Journal homepage
925
Views
28
CrossRef citations to date
0
Altmetric
Case Report

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination

An autopsy case

Yu Sawada Division of Cancer Immunotherapy; National Cancer Center Hospital East; Kashiwa, Chiba Japan; Department of Gastroenterology; Yokohama City University; Yokohama, Kanagawa Japan
,
Toshiaki Yoshikawa Division of Cancer Immunotherapy; National Cancer Center Hospital East; Kashiwa, Chiba Japan
,
Satoshi Fujii Division of Pathology; Research Center for Innovative Oncology; National Cancer Center Hospital East; Kashiwa, Chiba Japan
,
Shuichi Mitsunaga Division of Hepatobiliary & Pancreatic Medical Oncology; National Cancer Center Hospital East; Kashiwa, Chiba Japan
,
Daisuke Nobuoka Division of Cancer Immunotherapy; National Cancer Center Hospital East; Kashiwa, Chiba Japan
,
Shoichi Mizuno Division of Cancer Immunotherapy; National Cancer Center Hospital East; Kashiwa, Chiba Japan
,
Mari Takahashi Division of Cancer Immunotherapy; National Cancer Center Hospital East; Kashiwa, Chiba Japan
,
Chisako Yamauchi Division of Pathology; Research Center for Innovative Oncology; National Cancer Center Hospital East; Kashiwa, Chiba Japan
,
Itaru Endo Department of Gastroenterology; Yokohama City University; Yokohama, Kanagawa Japan
&
Tetsuya Nakatsura Division of Cancer Immunotherapy; National Cancer Center Hospital East; Kashiwa, Chiba JapanCorrespondence[email protected]
 show all
Pages 1228-1233 | Received 05 Nov 2012, Accepted 02 Mar 2013, Published online: 06 Mar 2013

References

  • Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 2006; 12:2817 - 25; http://dx.doi.org/10.1158/1078-0432.CCR-05-2856; PMID: 16675576
  • Greten TF, Forner A, Korangy F, N’Kontchou G, Barget N, Ayuso C, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010; 10:209; http://dx.doi.org/10.1186/1471-2407-10-209; PMID: 20478057
  • Greten TF, Manns MP, Korangy F. Immunotherapy of hepatocellular carcinoma. J Hepatol 2006; 45:868 - 78; http://dx.doi.org/10.1016/j.jhep.2006.09.004; PMID: 17046096
  • Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306:16 - 25; http://dx.doi.org/10.1016/S0006-291X(03)00908-2; PMID: 12788060
  • Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125:89 - 97; http://dx.doi.org/10.1016/S0016-5085(03)00689-9; PMID: 12851874
  • Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 2009; 34:649 - 56; PMID: 19212669
  • Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009; 100:1403 - 7; http://dx.doi.org/10.1111/j.1349-7006.2009.01206.x; PMID: 19496787
  • Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Katagiri T, et al. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 2004; 10:8630 - 40; http://dx.doi.org/10.1158/1078-0432.CCR-04-1177; PMID: 15623647
  • Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12:2689 - 97; http://dx.doi.org/10.1158/1078-0432.CCR-05-2267; PMID: 16675560
  • Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005; 65:6245 - 54; http://dx.doi.org/10.1158/0008-5472.CAN-04-4244; PMID: 16024626
  • Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012; 18:3686 - 96; http://dx.doi.org/10.1158/1078-0432.CCR-11-3044; PMID: 22577059
  • Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother 2004; 53:249 - 55; http://dx.doi.org/10.1007/s00262-003-0473-9; PMID: 14704832
  • Yoshikawa T, Nakatsugawa M, Suzuki S, Shirakawa H, Nobuoka D, Sakemura N, et al. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci 2011; 102:918 - 25; http://dx.doi.org/10.1111/j.1349-7006.2011.01896.x; PMID: 21281401
  • Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909 - 15; http://dx.doi.org/10.1038/nm1100; PMID: 15340416
  • Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52 - 60; http://dx.doi.org/10.1055/s-0030-1247132; PMID: 20175033
  • Oquiñena S, Guillen-Grima F, Iñarrairaegui M, Zozaya JM, Sangro B. Spontaneous regression of hepatocellular carcinoma: a systematic review. Eur J Gastroenterol Hepatol 2009; 21:254 - 7; http://dx.doi.org/10.1097/MEG.0b013e328324b6a2; PMID: 19279469
  • Sawada Y, Sakai M, Yoshikawa T, Ofuji K, Nakatsura T. A glypican-3-derived peptide vaccine against hepatocellular carcinoma. Oncoimmunology 2012; 1:1448 - 50; http://dx.doi.org/10.4161/onci.21351; PMID: 23243625
  • Nobuoka D, Yoshikawa T, Sawada Y, Fujiwara T, Nakatsura T. Peptide vaccines for hepatocellular carcinoma. Hum Vaccin Immunother 2013; 9:210 - 2; PMID: 23442593

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.